Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY: MRK )

125.40 -0.04 (-0.03%)
Streaming Delayed Price Updated: 10:11 AM EDT, Jul 17, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Merck & Co

< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
87 88 Next >
If You Invested $1000 In This Stock 5 Years Ago, You Would Have $2,000 Today
Via Benzinga
2 Top Biotech Stocks to Buy in February
Biotech stocks aren't all created equal -- these two are the best of the bunch. 
Via The Motley Fool
Should Investors Buy or Sell the Vaccinex Patent News?
Shares of Vaccinex, Inc. are higher on February 7 on news that the clinical-stage biotechnology company secured a patent. Is it time to buy or sell the news? 
Via MarketBeat
Topics Intellectual Property
Exposures Intellectual Property
Is Merck Stock a Buy After Its Post-Earnings Sell-Off?
Despite beating analysts’ expectations on the top and bottom lines, MRK stock fell after earnings. This article analyzes if investors should jump in 
Via MarketBeat
Analyst Upgrades Personalis; Says Biopharma Is Strong, Cash Burn Is Down
Via Benzinga
The 7 Most Undervalued Blue-Chip Stocks to Buy in February 2023
If you're looking for undervalued blue-chip stocks, we've come up with a list of seven stocks that you can consider adding. 
Via InvestorPlace
Merck (MRK) Q4 2022 Earnings Call Transcript
MRK earnings call for the period ending December 31, 2022. 
Via The Motley Fool
Merck Beats Earnings Estimates
Merck came out with quarterly earnings of $1.62 per share. 
Via Talk Markets
Market Rally Powers Higher On Tame Fed, Meta Earnings; Apple, Google, Amazon In Focus: Weekly Review
The major indexes continued to run despite mixed-to-weak earnings. 
Via Investor's Business Daily
Why Personalis Shares Are Trading Higher Today
Via Benzinga
Merck's Keytruda Plus Chemo Combo Aces Late-Stage Study In Advanced Endometrial Cancer Patients
Via Benzinga
Merck's Oral COVID-19 Treatment Might Be Linked To Spreading Mutations, Study Shows
According to some researchers, Merck & Co’s (NYSE: MRK) COVID-pill is giving rise to new mutations of the COVID-19 virus in some patients. 
Via Benzinga
Merck's 2023 Earnings Guidance Widely Missed; Shares Slide
The sales outlook, on the other hand, was in line with forecasts. 
Via Investor's Business Daily
Merck Beats On Q4 earnings, Anticipates Almost 80% Decline In COVID-19 Treatment Sales In 2023
Via Benzinga
Merck & Co Earnings Preview
Via Benzinga
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Met Primary Endpoint of Progression-Free Survival (PFS) as First-Line Therapy for Advanced or Recurrent Endometrial Carcinoma
From Merck & Co., Inc.
Via Business Wire
The 7 Most Undervalued Dow Stocks to Buy in February 2023
If you’re looking for the best deals among the most iconic enterprises, these are the most undervalued Dow stocks to buy. 
Via InvestorPlace
Why These 2 Stocks Made the Dow Miss the Market Rally
Even as the S&P 500 climbed, weaker performance from Dow components held the average back. 
Via The Motley Fool
US Stocks Higher, NASDAQ Adds Over 230 Points
US stocks traded higher this morning, with the NASDAQ gaining more than 230 points on Thursday. Following the market opening Thursday, the Dow traded up 0.02% to 34,092.96, while the NASDAQ rose 2.00%... 
Via Benzinga
Checking In With Merck Stock Before Earnings
Merck will report earnings before the open Thursday, Feb. 2. 
Via Talk Markets
Got $5,000? 3 Stocks to Hold for the Next 20 Years
Not every company is built to thrive -- or even survive -- for the long haul. These are. 
Via The Motley Fool
Nasdaq Futures Fly As Meta Keeps Tech Earnings' Buoyancy Intact: Will Apple, Amazon, Alphabet Toe In Line?
The index futures point to a mixed opening on Thursday, as tech earnings continue to be encouraging. 
Via Benzinga
Merck Announces Fourth-Quarter and Full-Year 2022 Financial Results
From Merck & Co., Inc.
Via Business Wire
3 No-Brainer Dividend Stocks to Buy Hand Over Fist in 2023
These healthcare titans are poised for a strong showing in 2023 and beyond. 
Via The Motley Fool
February PDUFA Catalysts Biotech Investors Must Know: Sanofi's Bleeding Disorder Drug, Regeneron's Twin Eylea Label Expansions, 3 Delayed Approvals And More
The year has started well for biopharma companies on the regulatory front, as most decisions handed out during January were positive. The Food and Drug Administration has already cleared four new... 
Via Benzinga
7 Healthcare Stocks That Will Be Big Winners in 2023
Healthcare stocks had a strong 2022 which will continue throughout 2023 making these picks ones to consider. 
Via InvestorPlace
Sector Shift Stalls Healthcare Stocks But Biotech Shows Gains In January
Biotech stocks are off to a great start in 2023 with the IBB up 4.5% and the XBI up 7.7%. 
Via Talk Markets
Down 14.5%, Is Pfizer Stock a Screaming Buy?
Pfizer's declining COVID-19 franchise and upcoming patent expirations have weighed heavily on its stock. 
Via The Motley Fool
Cassava Sciences Stock Undervalued with Its $124 Price Target?
Casava Sciences Inc (NASDAQ: SAVA) stock has been the topic of much controversy in its quest for FDA approval for its simufilam drug. The Company is a 
Via MarketBeat
Exposures Product Safety
Can Market Sustain Upward Momentum In Tech-Heavy Earnings Week? Apple, Amazon, AMD, Alphabet, Ford Among Key Quarterly Reports To Watch
With a full week of earnings behind us, it’s time to take stock of the fourth-quarter reporting season so far. Overall, the news flow has been mixed, although tech earnings have grossly disappointed. 
Via Benzinga
< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
87 88 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.